financetom
Business
financetom
/
Business
/
AbbVie's 45mg Dose of Lupron Depot to Treat Prostate Cancer Approved by Health Canada
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AbbVie's 45mg Dose of Lupron Depot to Treat Prostate Cancer Approved by Health Canada
Nov 17, 2025 7:33 AM

10:02 AM EST, 11/17/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that Canadian regulator Health Canada has approved its six-month 45mg dose of Lupron Depot to treat advanced prostate cancer.

The company said the new approval of Lupron Depot adds to its 7.5 mg, (1-Month), 22.5 mg (3-Month), and 30 mg (4-Month) strength doses.

Price: 234.73, Change: +2.37, Percent Change: +1.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved